Engflag

Flutensif

Quick links to important sections

Flutensif

Flutensif_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flutensif

Quick Facts

Property Description
Active ingredient Amlodipine and Indapamide
Form Oral Modified-release Tablet
Pharmacological class Antihypertensive Agents
Common use Management of Essential Hypertension
Origin Synthetic
Rx Status Prescription-only

Flutensif: Definition, Composition, and Type

Flutensif is a prescription-only Fixed-Dose Combination (FDC) medication that unites two distinct antihypertensive agents into a single, oral tablet. This structure is a type of Single-Pill Combination (SPC). Its synthetic composition features the active compounds Amlodipine and Indapamide. The drug is often structured as an oral modified-release tablet, a distinctive feature aimed at ensuring a stable delivery profile over time.

Amlodipine is chemically classified as a dihydropyridine derivative, and Indapamide is a sulfonamide derivative belonging to the thiazide-like diuretic class. The use of the FDC is clinically recognized for simplifying dosing, which can promote more consistent patient adherence in long-term cardiovascular management.

Pharmacological Classification and General Purpose

Flutensif falls under the major pharmacological class of Antihypertensive Agents, reflecting its fundamental role in blood pressure regulation. Its dual nature combines a Calcium Channel Blocker (Amlodipine) with a Thiazide-like Diuretic (Indapamide).

This combination is designed for the sustained blood pressure control necessary in treating essential hypertension, particularly in adult patients who have already achieved stable control using the two components administered separately. The pharmacological rationale for this dual approach involves the combined effects of reducing vascular resistance and managing fluid volume to lead to a more comprehensive and stable antihypertensive outcome. Clinical data confirms this two-pronged approach is an effective strategy for maintaining stable blood pressure over time.

Regulatory References

  1. Public Assessment Report (Flutensif)

What side effects are possible with Flutensif?

Possible Side Effects and Safety Information

The safety profile for Flutensif, based on regulatory documentation, details adverse reactions categorized by their frequency and the affected System Organ Class (SOC).

Adverse reactions are classified according to the MedDRA frequency framework: Very common (occurs in ge 1 in 10 people), Common (occurs in ge 1 in 100 but < 1 in 10 people), Uncommon, Rare, Very Rare, and Not Known.

Serious and Clinically Significant Adverse Reactions

Official labeling emphasizes the potential for serious pulmonary undesirable effects, including interstitial pneumonia, pulmonary oedema, and Acute Respiratory Distress Syndrome (ARDS), which are documented as rare but serious risks associated with one of the active components. These reactions require strict monitoring.

Common Adverse Reactions

The most commonly reported adverse reactions typically involve gastrointestinal disorders, such as nausea and vomiting, and nervous system disorders. The modified-release (SR) formulation was developed to potentially reduce the peak plasma concentrations of one component, which is a regulatory aim to decrease the incidence of dose-related effects, particularly hypokalaemia (low potassium).

Safety Restrictions and Monitoring

Flutensif is contraindicated in patients with known hypersensitivity to the active substances or any excipients. Caution is specifically advised for patients with a recent history of pulmonary infiltrates or pneumonia, as they may face a higher risk of developing serious pulmonary undesirable effects like ARDS. The medicine's composition is noted for potential hypersensitivity reactions related to excipients with known effects.

Overdose and Emergency Response

Overdose Scope

Element Official Regulatory Description
Documented overdose presentations Overdose is officially documented to present primarily as severe and prolonged hypotension, often accompanied by signs of excessive peripheral vasodilation and reflex tachycardia. The diuretic component may also lead to severe electrolyte disturbances, particularly life-threatening hypokalemia and hyponatremia, alongside signs of significant fluid and volume depletion.
Physiological systems affected The two systems most affected are the Cardiovascular system (risk of shock and arrhythmias) and the Metabolic system (severe electrolyte and volume imbalance).
Population-specific overdose notes The official labeling notes that elderly patients may be at a heightened risk for experiencing severe hyponatremia and hypokalemia associated with the Indapamide component.
Emergency-response statements For any suspected overdose, the primary mandate is to seek immediate emergency medical attention and initiate active cardiac and respiratory monitoring.
When immediate medical help is required Urgent help is required for any suspected overdose due to the potential for life-threatening outcomes, including circulatory shock and severe cardiac arrhythmias.

Overdose Classifications (High-Level)

Element Official Regulatory Description
Severity classification Classified as a serious event with the potential for life-threatening consequences, including shock and fatal outcomes.
Overdose-context constraints No specific antidote is known, and hemodialysis is unlikely to be of benefit due to the Amlodipine component's high protein binding.

Resulting Overdose Structure

Official overdose statements:

  • Overdose may cause severe hypotension leading to shock and potentially fatal outcomes.
  • Risk of life-threatening cardiac arrhythmias is documented, primarily due to severe hypokalemia.
  • Supportive measures include volume replacement, vasopressors for resistant hypotension, and aggressive electrolyte correction.

Connection to the overall overdose profile: Regulatory documents define the overdose profile by documenting two major, life-threatening clinical manifestations: profound hemodynamic instability and severe electrolyte derangement. This dual risk profile mandates that patients seek immediate emergency medical attention for any suspected overdose, requiring continuous ECG monitoring and aggressive volume and electrolyte replacement as officially described in the labeling.

Therapeutic Uses of Flutensif

Quick Facts About Flutensif

Condition Therapeutic Role
High Blood Pressure (Essential Hypertension) May help manage and sustain blood pressure at appropriate levels.
Fluid Retention (Edema) Used to address salt and fluid retention associated with congestive heart failure.

What Flutensif Treats: Main Uses and Benefits

Flutensif is a combination prescription product utilized to support the management of certain cardiovascular conditions. Its primary therapeutic domain is in the treatment of essential hypertension (high blood pressure) in adult individuals. Controlling and regulating blood pressure is a key component of a comprehensive health management plan.

The medication is also indicated for the management of salt and fluid retention, commonly referred to as edema, which is associated with congestive heart failure. By addressing this fluid buildup, the compound aims to support the overall function of the cardiovascular system. Flutensif is primarily intended as a maintenance therapy for patients whose conditions are already managed with its individual components at the same dose levels.

The medication is indicated as substitution therapy for the treatment of essential hypertension. This approach is intended to help individuals adhere to their prescribed regimen for blood pressure control.

Eligibility and Restrictions for Use

Official Eligibility and Restrictions

Flutensif is officially indicated as a substitution therapy for adult patients with essential hypertension who are already controlled using its individual components (Amlodipine and Indapamide) at the same dose level. Use is specifically not established in the pediatric population (children and adolescents) as no supporting data are available in regulatory documents.

Absolute Contraindications

This medicine must not be used in patients with the following conditions, as stated in official regulatory labeling:

  • Hypersensitivity to Amlodipine, Indapamide, or related drug classes (sulfonamides, dihydropyridine derivatives).
  • Severe renal failure (creatinine clearance below 30 mL/min).
  • Severe hepatic impairment or hepatic encephalopathy.
  • Hypokalaemia (abnormally low serum potassium levels).
  • Severe hypotension, cardiogenic shock, or aortic stenosis (obstruction of the left ventricular outflow tract).

Use in Pregnancy and Lactation

Flutensif is contraindicated during the second and third trimesters of pregnancy and is contraindicated during lactation (breastfeeding).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Flutensif (Amlodipine/Indapamide) documents specific interaction patterns with other substances. The profile establishes combinations that are strictly contraindicated and those that require monitoring due to the potential for altered exposure or additive effects.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substances/Categories
Contraindicated Combinations Lithium; QTc-prolonging agents (e.g., Class Ia and III Antiarrhythmics); Metformin (constrained by renal function); Aliskiren (in diabetic patients).
Exposure Modification Strong CYP3A4 Inhibitors (increase Amlodipine concentration); CYP3A4 Inducers (reduce Amlodipine concentration); Amlodipine increases exposure of Immunosuppressants (e.g., Ciclosporine) and Simvastatin.
Additive Pharmacodynamics Potassium-wasting agents (increased risk of hypokalaemia); NSAIDs (risk of reduced antihypertensive effect); Other antihypertensive drugs (risk of additive hypotensive effects).

Co-administration with Grapefruit or Grapefruit Juice can increase Amlodipine plasma concentration, and Alcohol (Ethanol) may contribute to orthostatic effects. Official regulatory labeling includes population-specific notes, indicating that the risk and severity of Amlodipine pharmacokinetic interactions are heightened in individuals with Hepatic Impairment due to reduced clearance. Furthermore, a dose restriction is formally mandated for Simvastatin when co-administered with Amlodipine.

Mechanism of Action

Flutensif operates through a dual-vector mechanism that addresses two main physical factors governing arterial pressure: vascular resistance and fluid volume.

Modulating Vascular Resistance via Calcium Channel Blockade

This domain centers on Amlodipine, which is an inhibitor that blocks L-type calcium channels (CaV 1.2) in arterial smooth muscle. By inhibiting the influx of calcium ions, the drug prevents the muscle cells from contracting. This intracellular consequence leads to vasodilation and a resultant decrease in total peripheral resistance. This mechanism establishes a sustained reduction in the stiffness and tone of the blood vessels.

Regulating Fluid Volume via Cotransporter Inhibition

This domain is defined by Indapamide's action on the kidney, where it inhibits the sodium-chloride cotransporter (NCC) in the distal convoluted tubule. This inhibition reduces the reabsorption of salt and water, initiating natriuresis and diuresis. This effect leads to a reduction in the intravascular fluid volume, which results in a decrease in the load on the circulatory system and contributes to lowering peripheral resistance.

The Complementary Mechanistic Synergy

The synergy of the combination lies in its ability to target vascular tone and fluid volume simultaneously. This combination helps modulate the body's natural volume-regulating systems that might otherwise limit the pressure-lowering effects of either component alone, leading to a combined physiological adjustment of arterial pressure.

Dosage and Administration Information

Administration Guidelines for Flutensif

Flutensif is an oral medication, provided as a modified-release tablet combining indapamide sustained-release and amlodipine.

Dosing and Administration

Instruction Domain Requirement (Substitution Therapy)
Standard Dose One modified-release tablet once daily.
Route & Form Must be swallowed whole; do not crush, chew, or split the tablet.
Timing & Food Take once daily at the same time, typically in the morning. May be taken with or without food.
Context of Use Approved for use as substitution therapy in patients whose blood pressure is already adequately controlled on the individual components (indapamide and amlodipine) taken concurrently at the same dose.

Population-Specific Instructions

  • Elderly Patients: No dose adjustment is strictly required in the elderly population.
  • Pediatric Use: Use in children and adolescents is not recommended due to a lack of established safety and efficacy data.
  • Renal/Hepatic Impairment: Flutensif is not recommended for patients with severe renal impairment (creatinine clearance < 30 mL/min) and should be used with caution in patients with hepatic impairment, as adjustments may be necessary.

Missed Dose

If a dose is forgotten, the patient should take the next dose at the usual scheduled time. The recommended procedure is that the patient must not take a double dose to compensate for a missed tablet.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Flutensif

Evidence for Use in Essential Hypertension as Substitution Therapy

The evidence for the Fixed-Dose Combination (FDC) tablet primarily supports its use as a substitution therapy. Research focused on patients whose blood pressure condition was stable taking the two components (Amlodipine and Indapamide) separately. Formal regulatory studies, known as bioequivalence studies, examined if the body absorbed and processed the components from the single FDC pill the same way as the two separate pills. Comparative Randomized Controlled Trials (RCTs) explored whether the FDC delivered similar changes in Systolic and Diastolic Blood Pressure (SBP/DBP) compared to the free-pill regimen in the populations studied.

Evidence for the Single-Pill Approach

Research has explored combining the two active ingredients into one pill. Observational studies that monitored patient behavior reported patterns of adherence that were associated with the single-pill combination compared to those managing the same dose using multiple tablets. This evidence contributes to the broader research landscape by describing how adherence patterns were associated with the single-pill approach.

Evidence in Specific Hypertensive Subgroups

Research examined the combination in specific patient subgroups, particularly older adults with Isolated Systolic Hypertension (ISH). This often involved post-hoc analyses or prospective observational studies which explored changes in SBP and the rate of patients reaching target SBP levels. These findings indicate patterns related to SBP changes, though the results apply only to the populations studied and do not reflect dedicated, large-scale RCTs for this specific condition.

Vascular-Related Outcomes Studied

Some research explored outcomes related to systemic or functional imbalance beyond just blood pressure. These studies monitored changes in surrogate endpoints, such as the regression of Left Ventricular Hypertrophy (LVH) (thickening of the heart muscle) and arterial stiffness. These findings describe patterns observed over short-term intervals and help contextualize the influence on these vascular outcomes.

What Remains Uncertain About the Research

The follow-up durations for the primary comparative studies were short, typically a few weeks to a few months. Long-term effects are not fully established by extensive, dedicated randomized controlled trials using this specific combination. While the research base is available for the FDC's role as a substitution therapy, there is limited information for long-term outcomes specifically from large-scale, cardiovascular event-driven RCTs that would provide the strongest available evidence regarding the prevention of events like heart attack or stroke.

Frequently Asked Questions (FAQ)

Common questions about Flutensif (FAQ)

Q: How does Flutensif work to lower my blood pressure?

Flutensif is a combination medicine that addresses blood pressure through a dual mechanism. One component, Amlodipine, works to relax and widen your blood vessels, reducing overall resistance. The other component, Indapamide, acts on the kidneys to help your body get rid of excess salt and water, which manages fluid volume. This combined action is designed to support a sustained reduction in arterial pressure, as described in official product information.

Q: How long will it take for Flutensif to start working after I take the first pill?

Official information indicates that one of the active components, Amlodipine, stays in the body for an extended period, which helps provide a sustained effect over 24 hours. The full, stable blood pressure lowering effect may take a few weeks of continuous daily use to be established.

Q: What are the most common side effects I should watch out for?

Regulatory documents state that most commonly reported side effects fall into the 'Common' category, meaning they occur in 1 to 10 out of every 100 people. These typically include gastrointestinal issues like nausea and vomiting, as well as issues like headache, dizziness, and swelling of the ankles or feet (oedema).

Q: Can I drink alcohol while I am taking Flutensif?

The official product labeling advises caution regarding alcohol consumption. Taking the medication with alcohol may increase the risk of orthostatic effects—this is when a person feels dizzy or light-headed when standing up suddenly. Official label information suggests monitoring alcohol intake.

Q: Is Flutensif safe to take during the first trimester of pregnancy?

The medicine is contraindicated (should not be used) during the second and third trimesters of pregnancy due to risks to the fetus. The official labeling states that treatment should be discontinued immediately if a pregnancy is detected. Official label information advises against use during the first trimester.

How should Flutensif be stored and disposed of?

How to Store and Dispose of Flutensif?

Flutensif (Amlodipine/Indapamide modified-release tablets) must be stored and handled according to the official requirements to maintain quality and safety.

Storage Conditions

  • Temperature: The product must be stored at a temperature not exceeding 30°C.
  • Protection: To maintain stability, the tablets must remain in the original carton and blister pack until the time of use, which protects them from environmental factors.
  • Safety: The medication must be kept out of the sight and reach of children.

Disposal Instructions

Proper disposal is required for unused or expired medicine. The product must not be thrown away via wastewater or standard household waste.

  • Protocol: Individuals should consult a pharmacist for guidance on how to safely dispose of the medicine in accordance with local pharmaceutical waste collection programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagBulgaria

flagEstonia

flagNetherlands

flagPortugal

Equivalent of Flutensif found in:

A-Z Index: